
Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Expert reviews favorable efficacy and durability 5-year results for cemiplimab plus chemotherapy versus chemotherapy in the EMPOWER-Lung 3 Part 2 trial.





